July 23, 2026 -- AnHorn Medicines today announced the successful completion of the first subject first dose in the Phase I clinical trial of AH-008, a first-in-class neuroprotective candidate being developed to prevent chemotherapy-induced peripheral neuropathy (CIPN). This milestone marks the clinical advancement of a novel therapeutic approach designed to address one of the most common and debilitating complications of cancer treatment. Chemotherapy-induced peripheral neuropathy (CIPN) is a fr

Company formed to advance SYN-001, an FDA-designated orphan and rare pediatric disease therapeutic candidate acquired from Nobias Therapeutics Phase IIb trial planned to further evaluate SYN-001 for the treatment of neuropsychiatric symptoms associated with 22q11.2 Deletion Syndrome (22q11DS) JULY 23, 2026 -- A consortium of European and US-based investors and Nobias Therapeutics today announced the launch of Synaptiq Therapeutics, a privately held, clinical-stage biotechnology company dedicate

July 23, 2026 -- Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase 1 clinical study evaluating BAT8013, an antibody drug conjugate (ADC) that targets CD25. The clinical trial is a multicenter, open-label Phase 1 clinical study in patients with advanced solid tumors to evaluate the safety and tolerability of BAT8013 and to determine the recommended Phase 2 dose. CD25, also known as interleukin-2 receptor alpha chai

The U.S. FDA has granted Fast Track designation to Lu AH69593, an oral orexin 2 receptor agonist, for the treatment of patients with narcolepsy The orexin 2 receptor is critically located in the main biological pathway involved in wakefulness and sleep-wake regulation Lu AH69593 is currently in Phase 1b development for patients with narcolepsy The designation marks an important regulatory milestone as Lundbeck advances a portfolio of programs for people living with sleep-wake disorders July 23,

July 23, 2026 -- Haisco Pharmaceutical Group claimed today their independently developed Class 1 innovative drug, Ciprocopan Succinate Tablets (development code: HSK39297), has received marketing approval from the National Medical Products Administration of China (NMPA) for the treatment of adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who are complement-inhibitor-naïve. This is Haisco's fifth innovative drug approved for marketing and represents an important advance in the treat

Financing led by Frazier Life Sciences with participation from Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, Pivotal bioVenture Partners and KCap Biotechnology Fund and all existing investors Proceeds to support ongoing late-stage global clinical development and commercialization preparation of dotinurad, a next-generation, once daily, oral URAT1 inhibitor with the potential to deliver best-in-class safety and efficac

Peer-reviewed publication of ProstACT SELECT1 results confirm the utility of 68Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach2. Consistent with previously reported results3, the publication highlights TLX591-Tx’s clinical differentiation and safety profile. TLX591-Tx, Telix’s lead PSMA-targeting rADC therapy candidate, is currently being evaluated in ProstACT Global Phase 3 study4 for advanced metastatic prostate cancer. July 22, 2026 -- Teli

July 22, 2026 -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that it has initiated the rolling submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for ALXN1840 (tiomolibdate choline, TMC), its first-in-class albumin tripartite complex (“ATC”) activator for the treatment of Wilson disease. The FDA ha

- PDUFA target action date of May 8, 2027 - If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1, representing a potential blockbuster opportunity for BridgeBio- Encaleret demonstrated consistent efficacy across all pre-specified primary and key secondary efficacy endpoints normalizing key markers of CaSR-driven disease biologywithout the need for calcium and vitamin D supplements, with a favorable safety and tolerability prof

Financing will support development of RN-014 and RN-032 and continued expansion of the company's kidney disease pipeline July 21, 2026 -- Rege Nephro Co., Ltd. ("Rege Nephro"), a clinical-stage biotechnology company focused on iPS cell-based kidney regenerative medicine and drug discovery, today announced the closing of a financing round totaling approximately US$10.6 million through the issuance of J-KISS (Japan-Keep It Simple Security) share acquisition rights. The proceeds are expected to su